Physician profile
Michael E Walsh
NPI 1588691711
$10,304.93
in general payments reported to CMS, 2019-2025
24 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $763 · 2021: $1,208 · 2022: $805 · 2023: $1,970 · 2024: $1,997 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,742 · Education: $46.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,742.40 |
| Education | $46.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,527.45 | 2019-2025 | Spravato, Invega, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $1,223.82 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,047.27 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $856.95 | 2019-2025 | Ingrezza |
| Abbvie INC. | $716.70 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $696.68 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $563.07 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $552.23 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $506.69 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $469.94 | 2019-2022 | |
| Allergan, INC. | $422.09 | 2019-2020 | |
| Axsome Therapeutics, INC. | $323.77 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $233.62 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $221.28 | 2023-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $190.38 | 2021-2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $163.82 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $117.12 | 2023-2024 | Dyanavel Xr |
| Shire North American Group INC | $109.86 | 2019 | |
| Avanir Pharmaceuticals, INC. | $106.35 | 2019 | |
| Bausch Health US, LLC | $72.64 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $62.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $48.71 | 2019-2020 | |
| Corium, LLC | $37.33 | 2022 | |
| Luye Pharma (USA) LTD. | $34.47 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.